Robin Feldman

Books
Journal Articles
  • Advertising Medicine: Selling the Cure, 26 Stan. Tech. L. Rev. 1 (2023). FULLTEXT SSRN
  • CalRx Biosimilar Insulin: California’s Initiative to Enter the Insulin Market, 183 JAMA Internal Med. 1043 (2023). URL
  • Insulin: California’s Initiative to Enter the Insulin Market, JAMA Internal Med. (2023). URL
  • Leading With the Trailing Edge: Facilitating Patient Choice for Insulin Products, 10 J. L. & Biosci. 1 (2023). FULLTEXT SSRN
  • Patent Term Extensions and the Last Man Standing, 42 Yale L. & Pol'y Rev. 1 (2023). FULLTEXT
  • Patents as Property for the Takings, 12 N.Y.U. J. Intell. Prop. & Ent. L. 198 (2023). FULLTEXT SSRN
  • A Patient Price Guide for Prescription Medication, 175 Annals Internal Med. 885 (2022) (with Natalie Feldman & Enrique Seoane-Vazquez). URL
  • Atomistic Antitrust, 63 Wm. & Mary L. Rev. 1869 (2022) (with Mark A. Lemley). FULLTEXT SSRN
  • Captive Generics: The Wolf in Sheep’s Clothing, 59 Harv. J. on Legis. 383 (2022). FULLTEXT SSRN
  • Challenges with Defining Pharmaceutical Markets and Potential Remedies to Screen for Industry Consolidation, 47 J. Health Pol. Pol'y & L. 583 (2022) (with Brent D. Fulton, Jamie R. Godwin, & Richard M. Scheffler). FULLTEXT
  • Designing Disruption in Pharmaceuticals, 28 B.U. J. Sci. & Tech. L. 1 (2022). FULLTEXT SSRN
  • Lochner Revenant: The Dormant Commerce Clause & Extraterritoriality, 16 NYU J.L. & Liberty 209 (2022) (with Gideon Schor). FULLTEXT
  • The Price Tag of 'Pay-for-Delay', 23 Colum. Sci. & Tech. L. Rev. 1 (2022). FULLTEXT SSRN
  • Trade Secrets in Biologic Medicine: The Boundary with Patents, 24 Colum. Sci. & Tech. L. Rev. 1 (2022). FULLTEXT SSRN
  • Understanding ‘Evergreening’: Making Minor Modifications Of Existing Medications To Extend Protections, 41 Health Aff. 801 (2022). URL
  • AI Governance in the Financial Industry, 27 Stan. J.L. Bus. & Fin. 94 (2022) (with Kara Stein). FULLTEXT
  • Combination Therapy Patents: A New Front in Evergreening, 39 Nature Biotech. 1504 (2021) (with Garth W. Strohbehn, Alec J. Kacew, Daniel A. Goldstein, & Mark J. Ratain). FULLTEXT
  • Negative Innovation: When Patents Are Bad for Patients, 39 Nature Biotech. 914 (2021) (with David A. Hyman, et al.). FULLTEXT
  • Physicians Treating Alzheimer’s Disease Patients Should Be Aware that Televised Direct-to-Consumer Advertising Links More Strongly to Drug Utilization in Older Patients, 81 J. Alzheimer's Disease 1169 (2021). FULLTEXT
  • The Devil in the Tiers, 8 J. L. & Biosci. 1 (2021). FULLTEXT
  • Naked Price and Pharmaceutical Trade Secret Overreach, 22 Yale J.L. & Tech. 61 (2020) (with Charles Graves). SSRN URL
  • Perverse Incentives: Why Everyone Prefers High Drug Prices -- Except for Those Who Pay the Bills, 57 Harv. J. on Legis. 303 (2020). FULLTEXT
  • Pharmaceutical 'Pay-for-Delay' Reexamined: A Dwindling Practice or a Persistent Problem?, 71 Hastings L.J. 959 (2020) (with Laura Karas & Gerard F. Anderson). FULLTEXT SSRN
  • The Arc of History in Patent Subject Matter, 11 Hastings Sci. & Tech. L.J. 1 (2020). FULLTEXT
  • The Burden on Society from Eleventh-Hour 'Citizen Petitions' Filed to Slow Generic Drugs, 79 Md. L. Rev. Online 1 (2020). SSRN URL
  • The Cancer Curse: Regulatory Failure by Success, 21 Colum. Sci. & Tech. L. Rev. 1 (2020). URL
  • Viral Licensing: Ensuring the Public Interest When Taxpayers Fund Pharmaceutical Research, 59 Santa Clara L. Rev. 641 (2020) (with Betty Chang Rowe & Rabiah Oral). URL
  • Artificial Intelligence in the Health Care Space: How We Can Trust What We Cannot Know, 30 Stan. L. & Pol'y Rev. 399 (2019) (with Ehrik Aldana & Kara Stein).
  • Pharmaceutical Industry Funding to Patient-Advocacy Organizations: A Cross-National Comparison of Disclosure Codes and Regulation, 42 Hastings Int'l & Comp. L. Rev. 453 (2019) (with Laura Karas, Ge Bai, So Yeon Kang & Gerard F. Anderson). FULLTEXT
  • The Fatal Attraction of Pay-for-Delay, 18 Chi.–Kent J. Intell. Prop. 249 (2019) (with Prianka Misra). FULLTEXT SSRN URL
  • Artificial Intelligence: The Importance of Trust & Distrust, 21 Green Bag 2d 201 (2018) (peer reviewed). FULLTEXT SSRN
  • Is Patent Enforcement Efficient?, 98 B.U. L. Rev. 649 (2018) (with Mark A. Lemley). FULLTEXT SSRN
  • May Your Drug Price Be Evergreen, 5 J. L. & Biosci. 590 (2018). FULLTEXT
  • The Sound & Fury of Patent Activity, 103 Minn. L. Rev. 1793 (2018) (with Mark A. Lemley). FULLTEXT SSRN
  • A Citizen’s Pathway Gone Astray — Delaying Competition from Generic Drugs, 376 New Eng. J. Med. 1499 (2017) (with Connie Wang). FULLTEXT
  • Empirical Evidence of Drug Companies Using Citizen Petitions to Hold Off Competition, 27 Competition 1 (2017) (with John Gray & Giora Ashkenazi). URL
  • Empirical Evidence of Drug Pricing Games - A Citizen's Pathway Gone Astray, 20 Stan. Tech. L. Rev. 39 (2017) (with Evan Frondorf, Andrew K. Cordova & Connie Wang). FULLTEXT SSRN
  • The Gender Gap in Startup Catalyst Organizations: Bridging the Divide between Narrative and Reality, 95 Or. L. Rev. 313 (2017) (with Alice Armitage and Connie Wang). FULLTEXT SSRN
  • Drug Wars: A New Generation of Generic Pharmaceutical Delay, 53 Harv. J. on Legis. 500 (2016) (with Evan Frondorf). FULLTEXT SSRN
  • Open Letter on Ethical Norms in Intellectual Property Scholarship, 29 Harv. J.L. & Tech. 339 (2016) (with Mark A. Lemley, Jonathan S. Masur, & Arti K. Rai). FULLTEXT SSRN
  • Patent Licensing, Technology Transfer and Innovation, 106 Am. Econ. Rev. 188 (2016) (with Mark A. Lemley). SSRN
  • Regulatory Property: The New IP, 40 Colum. J.L. & Arts 53 (2016). FULLTEXT SSRN
  • Startups and Unmet Legal Needs, 2016 Utah L. Rev. 575 (2016) (with Alice Armitage, Evan Frondorf, & Christopher Williams). FULLTEXT SSRN
  • The CRISPR Revolution: What Editing Human DNA Reveals About the Patent System's DNA, 64 UCLA L. Rev. Disc. 392 (2016). FULLTEXT SSRN
  • Do Patent Licensing Demands Mean Innovation?, 101 Iowa L. Rev. 137 (2015) (with Mark A. Lemley). FULLTEXT SSRN
  • Federalism, First Amendment & Patents: The Fraud Fallacy, 17 Colum. Sci. & Tech. L. Rev. 30 (2015). FULLTEXT SSRN
  • Patent Demands and Initial Public Offerings, 19 Stan. Tech. L. Rev. 52 (2015) (with Evan Frondorf). FULLTEXT SSRN
  • Coming of Age for the Federal Circuit, 17 Green Bag 2d 27 (2014). FULLTEXT
  • Ending Patent Exceptionalism & Structuring the Rule of Reason: The Supreme Court Opens the Door for Both, 15 Minn. J. L. Sci. & Tech. 61 (2014). FULLTEXT
  • Gene Patenting After the U.S. Supreme Court Decision—Does Myriad Matter?, 26 Stan. L. & Pol'y Rev. 16 (2014). URL
  • Human Cells and Cultural Property, 21 Int'l J. Cultural Prop. 243 (2014).
  • Patent Demands & Startup Companies: The View from the Venture Capital Community, 16 Yale J.L. & Tech. 236 (2014). FULLTEXT SSRN
  • Patent Trolling: Why Bio & Pharmaceuticals Are at Risk, 17 Stan. Tech. L. Rev. 773 (2014) (with W. Nicholson Price II). FULLTEXT
  • The Pace of Change: Non-Practicing Entities and the Shifting Legal Landscape, 18 Chapman L. Rev. 635 (2014).
  • Transparency, 19 Va. J.L. & Tech. 271 (2014). FULLTEXT SSRN
  • A Conversation on Judicial Decision-Making, 5 Hastings Sci. & Tech. L.J. 1 (2013). FULLTEXT SSRN
  • Copyright at the Bedside: Should We Stop the Spread?, 16 Stan. Tech. L. Rev. 623 (2013) (with John Newman). FULLTEXT SSRN
  • Intellectual Property Wrongs, 18 Stan. J.L. Bus. & Fin. 250 (2013). FULLTEXT SSRN
  • The AIA 500 Expanded: Effects of Patent Monetization Entities, 17 UCLA J.L. & Tech. 1 (2013) (with Tom Ewing & Sara Jeruss). URL
  • The America Invents Act 500: Effects of Patent Monetization Entities on US Litigation, 11 Duke L. & Tech. Rev. 357 (2012) (with Sara Jeruss & Joshua H. Walker). HEIN SSRN
  • The Giants Among Us, 2012 Stan. Tech. L. Rev. 1 (2012) (with Tom Ewing). FULLTEXT SSRN
  • Understanding and Incentivizing Biosimilars, 64 Hastings L.J. 57 (2012) (with Jason Kantor). FULLTEXT SSRN
  • Copyright and Open Access at the Bedside, 365 New Eng. J. Med. 2449 (2011) (with John C. Newman). URL
  • Whose Body Is It Anyway? Human Cells and the Strange Effects of Property and Intellectual Property Law, 63 Stan. L. Rev. 1377 (2011). FULLTEXT SSRN
  • The Intellectual Property Landscape for iPS Cells, 3 Stan. J.L. Sci. & Pol'y 16 (2010) (with Deborah Furth) (peer edited). FULLTEXT SSRN
  • The Role of the Subconscious in Intellectual Property Law, 2 Hastings Sci. & Tech. L.J. 1 (2010). FULLTEXT SSRN
  • Historic Perspectives on Law & Science, 2009 Stan. Tech. L. Rev. 1 (2009). FULLTEXT SSRN
  • Law's Misguided Love Affair with Science, 10 Minn. J. L. Sci. & Tech. 95 (2009) (peer edited). FULLTEXT SSRN
  • Plain Language Patents, 17 Tex. Intell. Prop. L.J. 289 (2009). FULLTEXT SSRN
  • Open Source, Open Access, Open Transfer: Market Approaches to Research Bottlenecks, 7 Nw. J. Tech. & Intell. Prop. 14 (2008) (with Kris Nelson) (reprinted in Open Source Software—Law and Philosophy ___ (Amicus Books 2009)). FULLTEXT SSRN
  • Patent and Antitrust: Differing Shades of Meaning, 13 Va. J.L. & Tech. 5 (2008). FULLTEXT SSRN
  • Rethinking Rights in Biospace, 79 S. Cal. L. Rev. 1 (2005). FULLTEXT SSRN
  • The Inventor's Contribution, 2005 UCLA J.L. & Tech. 6 (2005). FULLTEXT SSRN
  • The Open Source Biotechnology Movement: Is It Patent Misuse?, 6 Minn. J. L. Sci. & Tech. 117 (2004) (peer reviewed). FULLTEXT SSRN
  • Considerations on the Emerging Implementation of Biometric Technology, 25 Hastings Comm. & Ent. L.J. 653 (2003). FULLTEXT SSRN
  • The Insufficiency of Antitrust Analysis for Patent Misuse, 55 Hastings L.J. 399 (2003). FULLTEXT SSRN
  • Consumption Taxes and the Theory of General and Individual Taxation, 21 Va. Tax Rev. 293 (2002). FULLTEXT SSRN
  • Defensive Leveraging in Antitrust, 87 Geo. L.J. 2079 (1999). FULLTEXT SSRN
Chapters In Books
  • Intellectual Property: Naked Price & Pharmaceutical Trade Secret Overreach, in 5 The Judges' Book 93 (Scott Dodson ed., UC Hastings 2021). URL
  • Competition at the Dawn of Artificial Intelligence, in Competition Law for the Digital Economy 71 (Björn Lundqvist, & Michal S. Gal eds., Edward Elgar 2019) (with Nick Thieme) (peer reviewed). URL
  • Learning from Past Mistakes — The US Patent System and International Trade Agreements, in Megaregionalism 2.0: Trade and Innovation within Global Networks 145 (Dieter Ernst & Michael G. Plummer eds., World Scientific Studies in International Economics 2018). URL
  • Coming to the Community, in Imagining New Legalities: Privacy and Its Possibilities in the 21st Century 84 (Austin Sarat et al. eds., Amherst Series in Law, Jurisprudence & Social Thought, Stanford Univ. Press 2012). CATALOG URL
  • Patent Misuse: From Inception to Modern Case Law, in 2 Intellectual Property and Information Wealth: Issues and Practices in the Digital Age 137 (Peter K. Yu ed., Praeger Publishers 2007). CATALOG URL
Book Reviews
  • Book Review, 34 Governance 263 (2021) (reviewing Gerald Posner, Pharma: Greed, Lies, and the Poisoning of America). URL
  • For the Love of Licensing, 18 Va. J.L. & Tech. 178 (2013) (reviewing Cynthia Cannady, Technology Licensing and Development Agreements). URL
Newspaper & Magazine Articles
  • We Need a Labeling System for Pharmaceutical Prices, Wash. Post, Jun. 10, 2022 (with Natalie Feldman & Enrique Seoane-Vazquez). URL
  • Drug Companies Keep Merging. Why That’s Bad for Consumers and Innovation, Wash. Post, Apr. 6, 2021. URL
  • Our Patent System is Broken. And it Could Be Stifling Innovation, Wash. Post, Aug. 8, 2021 (Op-Ed). URL
  • What Is the Price of a Prescription Drug?, Promarket, Feb. 4, 2021. URL
  • ‘One-and-Done’ for New Drugs Could Cut Patent Thickets and Boost Generic Competition, STAT, Feb. 11, 2019. URL
  • The Perils of Value-Based Pricing for Prescription Drugs, Wash. Post, Apr. 11, 2019. URL
  • Why the Cancer “Moonshot” Has Been So Disappointing, Wash. Post, Sep. 14, 2019. URL
  • Why Prescription Drug Prices Have Skyrocketed, Wash. Post, Nov. 26, 2018. URL
  • How Big Pharma Is Hindering the Treatment of the Opioid Addiction Epidemic, The Conversation, Aug. 7, 2017. URL
  • Pharma Companies Fight Behind-the-Scenes Wars Over Generic Drugs, STAT, Jun. 16, 2017. URL
  • Next Patent Troll Victims: Pharma & Bio?, The Hill, Mar. 28, 2014. URL
  • FTC Must Move Quickly Against Patent Trolls, S.F. Chron., July 21, 2013. URL
  • You Patented It, You Own It? Not So Fast, Bos. Globe, Jan. 20, 2013. URL
  • Shedding Light on 'Prometheus', The Recorder, Mar. 9, 2012, at 10. LX
  • Slowing the Patent Trolls, N.Y. Times, Mar. 28, 0. URL
Other Publications
  • Incentivizing Failure, UC Hastings Research Paper (2021). URL
  • Pharmaceutical Pipeline Divestitures Study: Preliminary Results, UC Hastings Research Paper (2021). URL
  • States’ Rights: A Patent Law Analysis of NASHP Rate-Setting Model Act, National Association of State Health Policy White Paper (March 2018) (with Betty Chang Rowe, Rabiah Oral, Amy Y. Gu, & Katherine Gudiksen). URL
  • Learning from Past Mistakes — The US Patent System and International Trade Agreements, Working Paper, East-West Center Workshop on Mega-Regionalism - New Challenges for Trade and Innovation (2016). URL
  • Comment on the Food and Drug Administration (FDA) Notice: Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access (Sept. 18, 2017). URL
Search the Database

Search our faculty's bibliographies.

Get Help

Help using Faculty Bibliographies Search.

Faculty Services Librarian Tony Pelczynski compiles the Faculty Bibliographies database. Citation information is updated twice a year.